Table 1 Systemic diseases of the investigated cohort
Systemic disease | Preceding years n = 663 (%) | Covid-19 year n = 298 (%) | p-value |
|---|---|---|---|
Allergy | 164 (24.7) | 83 (27.9) | |
Lung disease total | 65 (9.8) | 32 (10.7) | |
Asthma | 40 (6.0) | 19 (6.4) | |
COPD | 16 (2.4) | 7 (2.3) | |
Chronic bronchitis | 3 (0.5) | 3 (1.0) | |
Tuberculosis | 1 (0.15) | 0 (0) | |
Pneumonia | 1 (0.15) | 0 (0) | |
COVID-19 | 0 (0) | 2 (0.7) | |
Others | 4 (0.6) | 1 (0.3) | |
Non-medication-related bleeding disorders total | 7 (1.1) | 5 (1.7) | |
Hemorrhagic diathesis Thrombophilia | 4 (0.6) | 2 (0.7) | |
3 (0.5) | 3 (1.0) | ||
Diabetes mellitus total | 52 (7.8) | 31 (10.4) | |
Diabetes mellitus type I | 5 (0.8) | 2 (0.7) | |
Diabetes mellitus type II | 47 (7.1) | 29 (9.7) | |
Cardiac disease total | 86 (13.0) | 46 (15.4) | |
Coronary heart disease | 54 (8.1) | 16 (5.4) | |
Myocardial Infarction | 15 (2.3) | 5 (1.7) | |
Arrhythmia | 36 (5.4) | 24 (8.1) | |
Pacemaker | 9 (1.4) | 3 (1.9) | |
Cardiac insufficiency | 24 (3.6) | 15 (5.0) | |
Conatal heart disease | 0 (0) | 2 (0.7) | |
Valve replacement | 6 (0.9) | 5 (1.7) | |
Hypertension | 179 (27.0) | 73 (24.5) | |
Vascular Disease | 42 (6.3) | 30 (10.1) | 0.042* |
Liver/ bile disease | 32 (4.8) | 14 (4.7) | |
Gastro-intestinal disease | 60 (9.0) | 25 (8.4) | |
Kidney disease total | 26 (3.9) | 12 (4.0) | |
Dialysis | 4 (0.6) | 1 (0.3) | |
Thyroid disease | 98 (14.8) | 33 (11.1) | |
Epilepsy | 19 (2.9) | 2 (0.7) | 0.032* |
Glaucoma | 7 (1.1) | 4 (1.3) | |
Rheumatic disease | 13 (2.0) | 9 (3.0) | |
Psychiatric disease | 87 (13.1) | 33 (11.1) | |
Neoplasia total | 64 (1.0) | 31 (10.4) | |
Benign | 4 (0.6) | 2 (0.7) | |
Semimalignant | 2 (0.3) | 2 (0.7) | |
Malignant after performed therapy | 53 (8.0) | 25 (8.4) | |
Malignant | 5 (0.8) | 2 (0.7) | |
Solid malignant head and neck tumor | 16 (2.4) | 6 (2.0) | |
Solid malignant tumor elsewhere | 33 (5.0) | 21 (7.0) | |
Haemato-oncological disease | 9 (1.4) | 5 (1.7) |